AstraZeneca has paused a £200m expansion of its Cambridge research site, stalling its entire £650m UK investment plan.
The project was expected to create 1,000 jobs, but joins the scrapped £450m vaccine facility in Merseyside.
The company confirmed the decision, citing regular reassessment of investment needs, but declined to comment further.
In contrast, AstraZeneca pledged \$50bn in US investments by 2030, including facilities in Virginia, Maryland, and Texas.
The pause adds to a week of setbacks for UK pharma, with Merck canceling a £1bn London research centre and cutting jobs.
Sir John Bell warned major pharmaceutical companies are turning away from the UK due to investment concerns.
Sanofi echoed the criticism, urging the Treasury to create a competitive life sciences plan before resuming investment.
Eli Lilly also froze its £279m London lab project, deepening fears for the UK’s ambition to be a science superpower.
Industry groups demand NHS pricing reforms, pressing for a reduced clawback rate to align with European standards.
AstraZeneca Halts £200m Cambridge Expansion Amid UK Pharma Turmoil
OMN AI
This article was created with the assistance of OMN AI, the AI-powered editorial platform developed by OMN Group. Every article is reviewed, fact-checked, and approved by a human journalist before publication to ensure accuracy and editorial quality. Learn more at https://omngroup.com
Keep Reading
Add A Comment
Craze News delivers powerful stories, breaking news, sports, and culture—bringing bold perspectives and timely updates to keep readers informed, inspired, and connected worldwide.
We’re social. Connect with us:
© 2026 Craze News. All Rights Reserved.
